Cancer Treatment Variability: Drug Storage in Lysosomes Impacts Effectiveness

The frustrating reality of cancer treatment is that what works for one patient often doesn’t work for another. Recent research is beginning to pinpoint why, and the answer lies not just in the cancer itself, but in how effectively drugs reach their target inside cancer cells. A new study published in Nature Communications reveals that microscopic compartments within cells, called lysosomes, can act as drug reservoirs, dramatically altering how cancer therapies function – or fail to function – across individuals.

Mapping Drug Delivery in Ovarian Cancer

For years, scientists have understood that getting a drug to a tumor isn’t enough. The drug must also accumulate within cancer cells at a sufficient concentration to be effective. Researchers at the MRC Laboratory of Medical Sciences (LMS), led by Dr. Louise Fets, focused on PARP inhibitors, a class of targeted drugs used to treat ovarian cancer, and sought to understand how these drugs distribute themselves within tumor tissue. Ovarian cancer was chosen as a focus because PARP inhibitors have shown significant promise in treating the disease, yet patient responses vary considerably. The study aimed to visualize and quantify this distribution directly.

The team employed a sophisticated technique involving thin slices of ovarian tumors, kept viable in a lab setting. These “explants” were then treated with PARP inhibitors, allowing researchers to observe drug movement in real human tumor tissue. Crucially, they combined this with mass spectrometry imaging, which creates detailed maps showing where drug molecules accumulate, and spatial transcriptomics, which reveals gene activity in different areas of the tumor. This dual approach allowed them to correlate drug concentration with cellular behavior.

“A novel aspect of this study was the use of mass spectrometry imaging to directly measure and visualise drug uptake in patient tumor tissue. Through the spatial mapping of drug molecules, we could pinpoint regions of high and low drug and compare gene expression, from the same tissue slice, using spatial transcriptomics,” explains Dr. Zoe Hall, senior author and Associate Professor at Imperial’s Department of Metabolism, Digestion, and Reproduction.

Lysosomes: Unexpected Drug Storage

The research revealed a surprising finding: PARP inhibitors weren’t spreading evenly throughout cancer cells. Instead, some drugs were being drawn into lysosomes, organelles responsible for cellular waste disposal and recycling. These lysosomes essentially trapped the drugs, preventing them from reaching their intended targets and instead creating internal reservoirs. This uneven distribution significantly impacts treatment efficacy.

Lysosomes function by breaking down cellular components, but they can also store molecules for later use. In this case, the study showed that certain PARP inhibitors, like rucaparib and niraparib, were being sequestered within lysosomes, released slowly over time. This leisurely release creates a variable drug exposure, with some cells receiving a high dose and others receiving very little. Interestingly, not all PARP inhibitors are affected; olaparib appears to bypass this lysosomal storage mechanism.

“We were surprised to see large variability in drug accumulation at the single-cell level. This variability was driven by the build-up of a drug in lysosomes, which are acting as reservoirs, increasing the exposure of cancer cells to drugs, by storing and releasing the drug when needed,” says Dr. Carmen Ramirez Moncayo, first author and Postdoctoral Researcher at the LMS.

Implications for Personalized Cancer Treatment

PARP inhibitors are currently used to treat ovarian, breast, and prostate cancers, and are undergoing clinical trials for other cancer types. As reported by A-Z Animals, understanding how these drugs are stored and distributed could lead to more tailored treatment strategies. If a patient’s tumor exhibits high lysosomal storage of a particular PARP inhibitor, doctors might consider alternative drugs or combination therapies.

The study highlights the importance of considering the internal cellular environment when designing cancer treatments. It’s not simply about delivering the drug to the tumor; it’s about ensuring it reaches the right place within the cancer cells to exert its effect. This realization is driving a shift towards more personalized approaches, where treatment decisions are based on the unique characteristics of each patient’s tumor.

Beyond PARP Inhibitors: A Broader Understanding of Drug Delivery

While this study focused on PARP inhibitors and ovarian cancer, the underlying principle – that intracellular drug distribution can significantly impact treatment efficacy – likely applies to other cancer therapies as well. The researchers acknowledge that the study was conducted on tumor tissue maintained outside the body, and that drug delivery in patients is complicated by the often-disorganized structure of tumor blood vessels. As ScienceDaily reports, future research will involve animal models and larger patient studies to investigate how drug delivery, tumor structure, and lysosomal storage interact in real-world clinical settings, including in cases of cancer relapse.

Dr. Louise Fets emphasizes the long-term goal: “By understanding how drugs are taken up into cells, we can understand whether this influences why cancer drugs work for some people and not for others. Eventually, we hope to be able to study the molecular signature of a patient’s tumor to facilitate tailor therapeutic approaches in a more personalized way.” The next steps involve refining these diagnostic techniques and developing strategies to overcome lysosomal drug storage, potentially by modifying the drugs themselves or by co-administering agents that disrupt lysosomal function. This research represents a significant step towards more effective and individualized cancer treatments.